Bobby Khan

Bobby Khan is the Chief Medical Officer of Repair Biotechnologies. He is a cardiologist and clinical investigator, serving as Professor of Medicine at the University of Central Florida School of Medicine. Dr. Khan has published nearly 90 peer-reviewed articles in the areas of cardiovascular and metabolic disorders in highly regarded scientific journals. He is co-founder of Carmel Biosciences, which was successful in receiving its first approved product by the United States Food and Drug Administration in early 2018. Dr. Khan has served as the principal investigator for several clinical trials.